诺和诺德(Novo Nordisk)寻求欧盟批准Semaglutide治疗肥胖症

2020-12-20 Allan MedSci原创

丹麦制药公司诺和诺德(Novo Nordisk)已向欧洲药品管理局(EMA)提交了营销许可申请,寻求批准每周一次的semaglutide用于体重管理。

丹麦制药公司诺和诺德(Novo Nordisk)已向欧洲药品管理局(EMA)提交了营销许可申请,寻求批准每周一次的semaglutide用于体重管理。Semaglutide是一种每周一次的胰高血糖素样肽1(GLP-1)类似物,旨在治疗肥胖症。

Novo STEP IIIa期试验的数据涉及4,500多例肥胖成年人。结果显示,与安慰剂相比,每周接受一次一次Semaglutide 2.4mg的肥胖患者在统计学上具有显著意义,并且体重减轻。据报道,接受Semaglutide治疗的患者体重减轻了15-18%。此外,在这些试验中,该治疗似乎具有良好的安全性和良好的耐受性,最常见的副作用是胃肠道副作用,但这些症状是短暂的、轻度或中度的。

Novo Nordisk执行副总裁兼首席科学官Mads Krogsgaard Thomsen说:“对于诺和诺德来说,这是一个里程碑,但更重要的是,它代表了一种新的治疗选择,具有改变欧洲肥胖者医疗管理的潜力”。

 

原始出处:

http://www.pharmatimes.com/news/novo_nordisk_eyes_eu_approval_for_once-weekly_semaglutide_1360212

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Tue Jun 01 08:01:41 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013552, encodeId=2dcf2013552b5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 08 00:01:41 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269476, encodeId=ba4a12694e651, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Tue Jun 01 08:01:41 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013552, encodeId=2dcf2013552b5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 08 00:01:41 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269476, encodeId=ba4a12694e651, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2021-03-08 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Tue Jun 01 08:01:41 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013552, encodeId=2dcf2013552b5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 08 00:01:41 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269476, encodeId=ba4a12694e651, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Tue Jun 01 08:01:41 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013552, encodeId=2dcf2013552b5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 08 00:01:41 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269476, encodeId=ba4a12694e651, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=)]
    2020-12-22 fengyi812
  5. [GetPortalCommentsPageByObjectIdResponse(id=1633179, encodeId=3e4716331e9b1, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Tue Jun 01 08:01:41 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013552, encodeId=2dcf2013552b5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 08 00:01:41 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269476, encodeId=ba4a12694e651, content=<a href='/topic/show?id=f6818192258' target=_blank style='color:#2F92EE;'>#肥胖症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81922, encryptionId=f6818192258, topicName=肥胖症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590039, encodeId=586d159003960, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Dec 22 03:01:41 CST 2020, time=2020-12-22, status=1, ipAttribution=)]

相关资讯

eLife:抑制食欲、增加饱腹感,这种激素让减肥不再是梦

肥胖症已在世界范围内达到流行病的程度,并影响了40%以上的美国成年人。肥胖者更有可能患上2型糖尿病、心血管疾病或慢性肾脏疾病。很难靠饮食和运动来减轻体重,而极少数人能坚持下来。

CELL METAB:第一个关注限制时间的饮食方案的人类临床试验

限制时间的饮食(TRF)方案已经越来越受欢迎;然而,很少有研究考察其减肥效果如何。

Mol Nutr Food Res:AvoB在饮食诱导的肥胖症中可防止脂肪毒性并改善胰岛素敏感性

本研究旨在评估牛油果衍生的脂肪酸氧化(FAO)抑制剂--牛油果素B(AvoB)在饮食诱导肥胖(DIO)模型和体外脂肪毒性模型中对葡萄糖和脂肪代谢的影响。此外,研究还确定了其在人类口服的安全性,研究结果

Am J Clin Nutr:胃旁路手术患者对膳食脂质的肠道反应

与膳食相关的肠道激素分泌的改变似乎对Roux-en-Y胃旁路术(RYGB)后的体重减轻和糖尿病缓解很重要。阐明其中发挥作用的膳食成分和受体可以帮助发现肥胖症和糖尿病的新疗法。肠内分泌细胞对膳食三酰甘油

J Nutrition:硫辛酸补剂有助于减肥

硫辛酸补充剂对血脂的作用是有限的。但是,那些通过硫辛酸减肥的人也降低了血液中甘油三酸酯的含量,这种作用是显而易见的。补充硫辛酸可以轻度降低氧化应激。结果表明补充硫辛酸可以是有益的。

Obesity 2020:Plenity(Gelesis100)治疗肥胖疗效明显

GLOW是一项关键性研究,结果表明,接受Plenity(Gelesis100)治疗的成年人在试验期间平均体重下降了13.5%,参与者平均接受Plenity(Gelesis100)治疗60天。

拓展阅读

肥胖症人群“生活方式”要转变!两大减肥反弹因素、三大干预目标值得关注!

European Heart Journal发表的一篇重磅综述指出,所有肥胖症患者应接受生活方式干预(如每天减少500千卡的摄入、每周散步150分钟)作为体重管理的基础干预策略。

JAMA子刊:吴寿岭教授团队发现肥胖症与心脏传导阻滞之间的关系

肥胖与CCB风险增加有关,其中I度房室传导阻滞(FABV)、高度房室传导阻滞(HAVB)和左前束支传导阻滞(LAFB)的风险增加幅度更大。同时,老年人和糖尿病患者的风险增加幅度更大。

近1600万人研究:近50%中国成人超重/肥胖!脂肪肝、糖尿病、血脂异常、高血压伴随高发

该论文同时指出,这是迄今为止在中国进行的关于全国超重和肥胖症患病率及相关并发症的最大规模的当代研究。

Nature重磅:国际大咖解答减重药物的“四大热门问题”

全球现下有超过十亿人患有肥胖症,超重的比例甚至更多。随着新型高效减重药物的出现,科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。

Cell Metabo:浙江大学发文揭示肥胖相关炎症的关键调控机制

靶向调控巨噬细胞介导的慢性炎症在治疗肥胖及相关的代谢紊乱中非常关键。

想减肥,“管住嘴迈开腿”只是正确的废话??听听曜影专家怎么说

过节一顿猛吃,好多人发现自己的腰围hold不住了,皮带要比原来松好几个眼儿才行;节后胖三斤,都是大吃大喝惹的祸吗?